Straits Times Index
3,269.61 -30.43 (-0.92%) Nikkei
38,212.23 -622.87 (-1.60%) Hang Seng
18,410.20 -69.17 (-0.37%) FTSE 100
8,313.67 +100.18 (+1.22%) Bitcoin USD
62,612.23 -763.88 (-1.21%) CMC Crypto 200
1,297.00 -68.12 (-4.98%)
Cumberland Pharmaceuticals Inc. (CPIX)
| Previous close | 1.5300 |
| Open | 1.5700 |
| Bid | 1.3300 x 200 |
| Ask | 2.1200 x 200 |
| Day's range | 1.5700 - 1.8372 |
| 52-week range | 1.4200 - 2.3600 |
| Volume | |
| Avg. volume | 10,445 |
| Market cap | 22.399M |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4400 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireCumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders' equity.
- PR Newswire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
- PR Newswire
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting the use of its Caldolor® product (intravenous ibuprofen, or IVIB) as a standard of care for the treatment of pain and fever in adults, children and infants.
